Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYP2C19 loss-of-function alleles and atherothrombotic events in clopidogrel-treated patients after EVAR
NL-OMON55153Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of clopidogrel in abdominal aortic aneurysm (AAA) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Incidence of major adverse cardiac events and major adverse limb events. Started Nov 2021; status: active, not recruiting.
02
Drugs
clopidogrel
03
Conditions
abdominal aortic aneurysm (AAA)
Beyond the preview
Go deeper on NL-OMON55153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55153.